Implications of the histological determination of microRNAs in the screening, diagnosis and prognosis of colorectal cancer

Journal of Surgical Oncology

Volumn 108, Issue 1, 2013, Pages 70-73

  Menéndez, Pablo ^a,e   Villarejo, Pedro ^b   Padilla, David ^b   Menéndez, José María ^c   Rodríguez Montes, José Antonio ^d  

^a Hospital Gutierrez Ortega   (Spain)

^b Hospital General   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e not available ^*  (Spain)

Author keywords

colorectal cancer; diagnosis; microRNA; prognosis; screening

Indexed keywords

CAPECITABINE; FLUOROURACIL; MICRORNA; OXALIPLATIN;

CANCER DIAGNOSIS; CANCER SCREENING; CARCINOGENESIS; COLORECTAL CANCER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 84879409768     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23344     Document Type: Review

References (39)

1. Mitchell PS, Parkin RK, Kroh EM, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
2. Menéndez P, Villarejo P, Padilla D, et al.: Diagnostic and prognostic significance of serum MicroRNAs in colorectal cancer. J Surg Oncol 2013; 107: 217-220.
3. Brase JC, Wuttig D, Kuner R, et al.: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010; 9: 306.
4. Heneghan HM, Miller N, Lowery AJ, et al.: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
5. Tsujiura M, Ichikawa D, Komatsu S, et al.: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-1179.
6. Ho AS, Huang X, Cao H, et al.: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010; 3: 109-113.
7. Liu CJ, Kao SY, Tu HF, et al.: Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010; 16: 360-364.
8. Hu Z, Chen X, Zhao Y, et al.: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28: 1721-1726.
9. Schetter AJ, Harris CC:, Plasma microRNAs: a potential biomarker for colorectal cancer ? Gut 2009; 58: 1318-1319.
10. Tam W:, The emergent role of microRNAs in molecular diagnostics of cancer. J Mol Diagn 2008; 10: 411-414.
11. Miller S, Steele S:, Novel molecular screening approaches in colorectal cancer. J Surg Oncol 2012; 105: 459-467.
12. Ahmed FE, Jeffries CD, Vos PW, et al.: Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009; 6: 281-295.
13. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al.: Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 2011; 46: 1391-1402.
14. Koga Y, Yasunaga M, Takahashi A, et al.: MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010; 3: 1435-1442.
15. Link A, Balaguer F, Shen Y, et al.: Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-1774.
16. Wu CW, Ng SS, Dong YJ, et al.: Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012; 61: 739-745.
17. Luo X, Burwinkel B, Tao S, et al.: MicroRNA signatures: novel biomarker for colorectal cancer ? Cancer Epidemiol Biomarkers Prev 2011; 20: 1272-1286.
18. Manne U, Shanmugam C, Bovell L, et al.: miRNAs as biomarkers for management of patients with colorectal cancer. Biomark Med 2010; 4: 761-770.
19. Schmitz KJ, Hey S, Schinwald A, et al.: Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch 2009; 455: 49-54.
20. Yamamichi N, Shimomura R, Inada K, et al.: Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 2009; 15: 4009-4016.
21. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al.: MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009; 101: 707-714.
22. Chang KH, Mestdagh P, Vandesompele J, et al.: MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 2010; 10: 173.
23. Xi Y, Formentini A, Chien M, et al.: Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006; 2: 113-121.
24. Zhai H, Ju J:, Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics. Front Genet 2011; 2: pii: 00078.
25. Motoyama K, Inoue H, Takatsuno Y, et al.: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34: 1069-11075.
26. Schetter AJ, Leung SY, Sohn JJ, et al.: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
27. Slaby O, Svoboda M, Fabian P, et al.: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
28. Shibuya H, Iinuma H, Shimada R, et al.: Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-320.
29. Vickers MM, Bar J, Gorn-Hondermann I, et al.: Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 2012; 29: 123-132.
30. Dong Y, Wu WK, Wu CW, et al.: MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer 2011; 104: 893-898.
31. Schetter AJ, Harris CC:, Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 2011; 38: 734-742.
32. Corté H, Manceau G, Blons H, et al.: MicroRNA and colorectal cancer. Dig Liver Dis 2012; 44: 195-200.
33. Panarelli NC, Yantiss RK:, MicroRNA expression in selected carcinomas of the gastrointestinal tract. Pathol Res Int 2011; 2011: 124608.
34. Song B, Wang Y, Titmus MA, et al.: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010; 9: 96.
35. Song B, Wang Y, Xi Y, et al.: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065-4074.
36. Drebber U, Lay M, Wedemeyer I, et al.: Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 2011; 39: 409-415.
37. Ragusa M, Majorana A, Statello L, et al.: Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 2010; 9: 3396-3409.
38. Della Vittoria Scarpati G, Falcetta F:, Carlomagno C, et al.: A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1113-1119.
39. voboda M, Izakovicova Holla L, Sefr R, et al.: Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol 2008; 33: 541-547.